Rodin Therapeutics Inc. announced a private placement of preferred shares for gross proceeds of $17,300,000 on January 6, 2016. The transaction included participation from returning investor, Atlas Venture L.P. and new investor Biogen Inc. As part of the round, Samantha Budd Haeberlein of Biogen Inc. will join the company's board of directors.